| Literature DB >> 31220191 |
Lylia Hani1,2,3, Antoine Chaillon3,4, Marie-Laure Nere5, Nicolas Ruffin1,2,3, Joudy Alameddine1,2,3, Maud Salmona5, José-Luiz Lopez Zaragoza1,2,3,6, Davey M Smith4, Olivier Schwartz3,7, Jean-Daniel Lelièvre1,2,3,6, Constance Delaugerre3,5, Yves Lévy1,2,3,6, Nabila Seddiki1,2,3.
Abstract
We previously reported the presence of memory CD4+ T cells that express low levels of SAMHD1 (SAMHD1low) in peripheral blood and lymph nodes from both HIV-1 infected and uninfected individuals. These cells are enriched in Th17 and Tfh subsets, two populations known to be preferentially targeted by HIV-1. Here we investigated whether SAMHD1low CD4+ T-cells harbour replication-competent virus and compartimentalized HIV-1 genomes. We sorted memory CD4+CD45RO+SAMHD1low, CD4+CD45RO+SAMHD1+ and naive CD4+CD45RO-SAMHD1+ cells from HIV-1-infected patients on anti-retroviral therapy (c-ART) and performed HIV-1 DNA quantification, ultra-deep-sequencing of partial env (C2/V3) sequences and phenotypic characterization of the cells. We show that SAMHD1low cells include novel Th17 CCR6+ subsets that lack CXCR3 and CCR4 (CCR6+DN). There is a decrease of the % of Th17 in SAMHD1low compartment in infected compared to uninfected individuals (41% vs 55%, p<0.05), whereas the % of CCR6+DN increases (7.95% vs 3.8%, p<0.05). Moreover, in HIV-1 infected patients, memory SAMHD1low cells harbour high levels of HIV-1 DNA compared to memory SAMHD1+ cells (4.5 vs 3.8 log/106cells, respectively, p<0.001), while naïve SAMHD1+ showed significantly lower levels (3.1 log/106cells, p<0.0001). Importantly, we show that SAMHD1low cells contain p24-producing cells. Moreover, phylogenetic analyses revealed well-segregated HIV-1 DNA populations with compartmentalization between SAMHD1low and SAMHD1+ memory cells, and limited viral exchange. As expected, the % of Ki67+ cells was significantly higher in SAMHD1low compared to SAMHD1+ cells. There was positive association between levels of HIV-1 DNA and Ki67+ in memory SAMHD1low cells, but not in memory and naïve SAMHD1+ CD4+ T-cells. Altogether, these data suggest that proliferative memory SAMHD1low cells contribute to viral persistence.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31220191 PMCID: PMC6605680 DOI: 10.1371/journal.ppat.1007868
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 1Memory CD4+ SAMHD1low cells are depleted in c-ART HIV-1 infected patients and enriched in Th17-polarized CCR6+ populations.
Fresh PBMCs from HIV-1 negative (HIV-, n = 13) and HIV-1 infected individuals receiving c-ART (cART+ HIV-1+, n = 17) were stained with a cocktail of fluorochrome-conjugated -CD3, -CD4, -CD45RO, -CXCR3, -CCR4, -CCR6 and -SAMHD1 monoclonal antibodies. A viability staining was used to exclude dead cells. (a) Gating strategy for naïve SAMHD1+ (CD45RO- SAMHD1+), memory SAMHD1+ (CD45RO+SAMHD1+), memory SAMHD1low (CD45RO+SAMHD1low) cells. (b) Percentages of memory SAMHD1low cells among total memory CD4+ T-cells from HIV- and c-ART+ HIV-1+ patients. (c) Gating strategy for memory SAMHD1+ and SAMHD1low cells among T helper 17 (Th17: CD45RO+CXCR3-CCR4+CCR6+), Th1/Th17 (CD45RO+CXCR3+CCR4-CCR6+), CCR6+ double positive DP (CCR6+CXCR3+CCR4+), CCR6+ double negative DN (CCR6+CXCR3-CCR4-) cells. (d) Percentages of CCR6+ Th17, Th1/17, R6+ (CCR6+) DN, R6+DN cells among gated memory SAMHD1low CD4+ T-cells in uninfected vs HIV infected individuals. Data represent median with interquartile range. *p<0.05 and ***p<0.001, unpaired t-test.
Fig 2Memory CD4+ SAMHD1low cells are enriched in Th17 cells.
(a) Gating strategy for CCR6+ Th17, Th1/17, R6+DP and R6+DN cells. (b) Percentages of CCR6+ Th17, Th1/17, R6+DP, R6+DN cells among gated memory SAMHD1low CD4+ T-cells in uninfected vs HIV infected individuals (c) Percentages of CCR6+ Th17 and R6+DN cells among gated memory SAMHD1low and SAMHD1+ CD4+ T-cells in uninfected vs HIV infected individuals. (d) Percentages of CCR6+ Th17, Th1/17, R6+DP and R6+DN cells among gated memory SAMHD1low and SAMHD1+ CD4+ T-cells. Data represent median with interquartile range. *p<0.05, t-test and 2-way ANOVA tests followed by Bonferroni post-tests.
c-ART and VIR HIV+ patients.
| Characteristics of the study population | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| N Pt | Gender | Age | Duration of treatment (years) | Time from HIV-1+ | CD4 count/ml | CD8 count/ml | CD3 count/ml | VL (copies/ml) | Nadir CD4 |
| M | 65 | 4 | 471 | 414 | 892 | <20 | 319 | ||
| M | 75 | 18 | 657 | 509 | 1165 | <20 | 158 | ||
| M | 74 | 16 | 590 | 581 | 1238 | <20 | 254 | ||
| F | 45 | 15 | 893 | 1140 | 2018 | <20 | 212 | ||
| F | 37 | 1 | 431 | 548 | 991 | <20 | 210 | ||
| F | 52 | 16 | 1393 | 1009 | 2410 | <20 | 237 | ||
| F | 39 | 10 | 347 | 403 | 813 | <20 | 167 | ||
| F | 40 | 9 | 619 | 417 | 1036 | <20 | 137 | ||
| M | 57 | 19 | 621 | 567 | 1212 | <20 | 155 | ||
| F | 51 | 20 | 549 | 413 | 978 | <20 | 274 | ||
| M | 74 | 18 | 458 | 511 | 972 | <20 | 218 | ||
| F | 58 | 13 | 1229 | 1203 | / | <20 | 389 | ||
| M | 69 | 11 | 860 | 1257 | 2089 | <20 | 162 | ||
| M | 67 | 12 | 741 | 533 | 1306 | <20 | 156 | ||
| M | 61 | 34 | 311 | 242 | 579 | <20 | 179 | ||
| M | 74 | 17 | 500 | 586 | 1138 | <20 | 254 | ||
| F | 45 | 16 | 643 | 781 | 1425 | <20 | 212 | ||
| M | 69 | 20 | 587 | 575 | 1158 | 22 | 100 | ||
| F | 51 | 8 | 606 | 315 | 997 | <20 | 108 | ||
| M | 42 | 3 | 385 | 905 | 1329 | <20 | 220 | ||
| F | 40 | 7 | 604 | 486 | 1097 | <20 | 137 | ||
| M | 51 | 3 | 436 | 657 | 1110 | <20 | 310 | ||
| M | 49 | 16 | 522 | 823 | 1371 | <20 | 178 | ||
| M | 62 | 13 | 596 | 467 | 1057 | <20 | 174 | ||
| F | 60 | 21 | 774 | 583 | 1378 | <20 | 169 | ||
| M | 66 | 10 | 601 | 1125 | 1712 | <20 | 45 | ||
| F | 72 | 14 | 1080 | 469 | 1554 | <20 | 528 | ||
| M | 69 | 18 | 499 | 518 | 1022 | <20 | 100 | ||
| M | 60 | 16 | 740 | / | / | <20 | 250 | ||
| F | 65 | 6 | 558 | 523 | 1101 | <20 | 30 | ||
| F | 34 | 1 | 550 | 267 | 862 | <20 | 367 | ||
| M | 37 | 14 | 269 | 1024 | 1340 | <20 | 176 | ||
| F | 56 | 11 | 951 | 1124 | 2063 | <20 | 185 | ||
| M | 57 | 18 | / | / | / | / | 175 | ||
| F | 72 | 18 | 1357 | 627 | 2039 | <20 | 545 | ||
| M | 41 | 1 | 423 | 321 | 772 | <20 | 350 | ||
| F | 57 | 20 | 398 | 522 | 979 | <20 | 135 | ||
| M | 57 | 7 | 129 | 789 | 990 | <20 | 4 | ||
| M | 41 | 12 | 490 | 668 | 1213 | <20 | 114 | ||
| M | 52 | 9 | 401 | ND | ND | <20 | 399 | ||
| M | 49 | 6 | 139 | 689 | 845 | <20 | 107 | ||
| M | 49 | 23 | 633 | ND | ND | <20 | 343 | ||
| M | 49 | 8 | 436 | 657 | 1110 | <20 | 310 | ||
| M | 45 | 21 | 522 | 823 | 1371 | <20 | 178 | ||
| M | 38 | 8 | 385 | 905 | 1329 | <20 | 220 | ||
| F | 36 | 14 | 666 | 1130 | 1839 | 86 | 193 | ||
| M | 49 | 23 | 714 | 417 | 1139 | <20 | 261 | ||
| F | 61 | 14 | 879 | 697 | 1582 | <20 | 209 | ||
| M | 53 | 21 | 418 | 835 | 1275 | <20 | 175 | ||
| F | 58 | 17 | 793 | 901 | 1731 | <20 | 222 | ||
| F | 40 | 13 | 747 | 763 | 1142 | <20 | 114 | ||
| M | 36 | 8 | 460 | 363 | 850 | <20 | 233 | ||
| M | 55 | 24 | 756 | 436 | 1237 | <20 | 261 | ||
| M | 55 | 22 | 1020 | 624 | 1654 | <20 | 191 | ||
| M | 46 | 5 | 489 | 997 | 1620 | <20 | 297 | ||
| M | 53 | 20 | 664 | 393 | 1072 | <20 | 210 | ||
| M | 40 | none | 325 | 806 | 1142 | 27000 | 325 | ||
| F | 31 | none | 468 | 606 | 1096 | 101 | 510 | ||
| F | 32 | none | 199 | 263 | 484 | 5647 | 199 | ||
EC patients.
| Characteristics of the study population | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| N Pt | Gender | Age | Time from HIV-1+ | CD4 | CD8 | CD3 | VL (copies/ml) | Treatment | Nadir CD4 |
| M | 48 | 33 | 783 | 1220 | 2172 | 244 | naif | 332 | |
| F | 52 | 33 | 1129 | 394 | 1548 | 0 | naif | 1106 | |
| F | 45 | 29 | 943 | 675 | 1638 | 308 | naif | 441 | |
| F | 33 | 17 | 737 | 337 | 1123 | 0 | naif | 687 | |
| F | 55 | 34 | 1483 | 875 | 2520 | 188 | naif | 1110 | |
| M | 26 | 6 | 857 | 994 | 1941 | 0 | naif | 628 | |
Fig 3Memory CD4+ CD45RO+ SAMHD1low cells exhibit the highest level of HIV-1 DNA.
Peripheral blood samples were collected from 36 HIV-infected individuals receiving c-ART and 6 Elite Controllers. Fresh PBMCs were stained with anti-CD3, -CD4, -CD45RO and -SAMHD1. The three cell subsets: memory CD4+ CD45RO+ SAMHD1low, CD4+ CD45RO+ SAMHD1+ and naive CD4+ CD45RO- SAMHD1+ were sorted by FACS. Protocols for DNA extraction and PCR experiments on permeabilized and fixed cells have been optimized using bulk PBMCs from 10 HIV-1 infected individuals receiving c-ART. Levels of total HIV-1 DNA were quantified by Nested real-time PCR in sorted cells ex vivo. (a) Gating strategy for memory CD4+CD45RO+SAMHD1low, CD4+CD45RO+SAMHD1+ and naive CD4+CD45RO-SAMHD1+. (b) Levels of total HIV-1 DNA in unfixed PBMCs from HIV-1 infected individuals receiving c-ART (n = 10) compared head-to-head with fixed PBMCs from the same individuals. (c) Levels of total HIV-1 DNA in sorted memory CD4+CD45RO+SAMHD1low, CD4+CD45RO+SAMHD1+ and naive CD4+CD45RO-SAMHD1+ from HIV-1 infected individuals receiving c-ART. (d) Levels of total HIV-1 DNA in sorted memory CD4+CD45RO+SAMHD1low, CD4+CD45RO+SAMHD1+ and naive CD4+CD45RO-SAMHD1+ from Elite Controllers (HIV+ EC). (e) Levels of total HIV-1 DNA in sorted naive CD4+CD45RO-SAMHD1+ from HIV-1 infected individuals receiving c-ART and Elite Controllers. Data represent median with interquartile range. *p<0.05, **p<0.01 and ***p<0.001, t-test and 2-way ANOVA tests followed by Bonferroni post-tests.
Fig 5Detection of p24-producing cells in memory CD4+ CD45RO+ SAMHD1low, CD4+ CD45RO+ SAMHD1+ and naive CD4+ CD45RO- SAMHD1+ subsets.
Samples from 3 viremic (VIR) and 7 c-ART individuals were used. 3 HIV-negative control were included. (a) Representative dot plots showing the p24 KC57-PE / p24 28B7-APC co-staining in purified CD4+ T cells stimulated with anti-CD3/CD28 antibodies for 48h. P24+ cells in memory CD4+ CD45RO+ SAMHD1low, CD4+ CD45RO+ SAMHD1+ and naive CD4+ CD45RO- SAMHD1+ subsets are shown (b) Frequencies of p24+ cells in each subset from c-ART and VIR HIV+ individuals are represented by histograms. Data represent median with interquartile range. Unpaired t test was applied for comparison between two subsets; *p<0.05, **p<0.01. Dotted-line points to the non-specific staining observed in HIV- individuals.